Ad
related to: dabrafenib/ trametinib mechanism of action- Read the Access Brochure
Learn about reimbursement support
and access for OJEMDA
- Sign Up for Updates
Sign up to stay informed
about the latest data
- Contact a Rep
Learn why OJEMDA might be right
for your pediatric patients
- See Instructions for Use
Help your patients get started
with OJEMDA. Read this guidance.
- Read the Access Brochure
Search results
Results from the WOW.Com Content Network
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
Trametinib, sold under the brand name Mekinist among others, is an anticancer medication used for the treatment of melanoma [4] [5] and glioma. [ 6 ] [ 7 ] It is a MEK inhibitor drug with anti-cancer activity. [ 8 ]
Pharmaceutical giant GlaxoSmithKline announced in a press release that it has begun a phase 3 study to find out whether two of its drugs -- its BRAF inhibitor dabrafenid and MEK inhibitor ...
Mechanism of action ... In January 2015, trial results compared vemurafenib with the combination of dabrafenib and trametinib for metastatic melanoma. [22]
Brigatinib is an inhibitor of ALK [3] and mutated EGFR. [5]ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL.
Binimetinib is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK), or more specifically, a MAP2K inhibitor. [9] MEK is part of the RAS pathway, which is involved in cell proliferation and survival.
Immunotherapy: mechanism of action for Durvalumab, Pembrolizumab, Ipilimumab, Atezolizumab. [20]A phase Ib clinical trial of durvalumab and tremelimumab showed some activity in non-small cell lung cancer (NSCLC) [21] Phase I data in advanced metastatic urothelial bladder (Study 1108) has led to FDA breakthrough therapy designation.
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).
Ad
related to: dabrafenib/ trametinib mechanism of action